Gustavo Del Toro
- ADJUNCT ASSOCIATE PROFESSOR Pediatrics
- As Director of the Pediatric Hematopoietic Cell Transplant Service, Dr. Del Toro specializes in hematopoietic cell transplantation for infants, children, and adolescents. The Pediatric Hematopoietic Cell Transplant Service provides complete pre-, peri-, and post-transplant care for pediatric patients who require transplantation of cord blood, marrow, or peripheral blood stem cells. This includes patients with oncological diseases such as acute leukemias and lymphomas as well as non-cancer diseases such as sickle cell disease, thalassemia, aplastic anemia, and congenital immune deficiencies.
Since Dr. Del Toro's arrival at Mount Sinai Kravis Children's Hospital in July, 2006, the Pediatric Hematopoietic Cell Transplant Service has been very active performing transplants in infants, children, and adolescents. The service shares all transplant facilities and ancillary services with the Adult Bone Marrow Transplant Service of Mount Sinai Hospital.
Dr. Del Toro also specializes in the diagnosis and treatment of varied pediatric cancers, including leukemias, lymphomas, and varied tumors.
Originally from Santurce, Puerto Rico, Dr. Del Toro attended the University of California, Los Angeles, the University of Michigan Medical School and trained at Miami Children's Hospital and Memorial Sloan-Kettering Cancer Center. He worked at Columbia University, College of Physicians and Surgeons as a pediatric oncologist and pediatric hematopoietic cell transplant specialist for many years before joining Mount Sinai Kravis Children's Hospital. Dr. Del Toro is the Chair of the annual Chemotherapy Foundation Symposium's Pediatric Oncology Session
Dr. Del Toro's research interests lie in the use of in-vitro fertilization with therapeutic intent for sickle cell disease, the treatment of graft-vs.-host disease, the use of hematopoietic cell transplantation for inborn errors of metabolism, and the potential of combined hematopoietic/solid organ transplantation.
Dr. Del Toro is an Associate Professor of Pediatrics and sees patients in his clinic every Monday and Wednesday as well as other days by appointment.
The Patrick John Niland Award
The University of Michigan Medical School
Del Toro G. Liver Tumors. In: Weiner M, Cairo M, editors. Pediatric Hematology/Oncology Secrets
Liver Tumors. Hanley and Belfus; 2002. pp155-56.
Del Toro G, Satwani P, Harrison L, Cheung YK, Brigid Bradley M, George D, Yamashiro DJ, Garvin J, Skerrett D, Bessmertny O, Wolownik K, Wischhover C, Van De Ven C, Cairo MS. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients.. Bone Marrow Transplant 2004 Mar; 33(6): 613-22.
Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol 2005 Jan; 3(1): 54-61.
Del Toro G, Morris E, Cairo M. Blood and Marrow Transplantation. In: Burg F, Ingenlfinger J, Polin R, Gershon A, editors. Current Pediatric Therapy
Blood and Marrow Transplantation. Saunders Elsevier; 2006. pp1166-73.
Del Toro G. Defibrotide in sinusoidal obstruction syndrome: mounting evidence in pediatric patients (Commentary on Qureshi et al., page 831). Pediatric Blood and Cancer 2008; 50(4): 735-736.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Del Toro is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.